Short Interest in ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Decreases By 9.2%

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) was the recipient of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totalling 269,900 shares, a decrease of 9.2% from the May 31st total of 297,400 shares. Approximately 1.2% of the company’s shares are sold short. Based on an average daily volume of 433,000 shares, the days-to-cover ratio is currently 0.6 days.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ASLN shares. HC Wainwright reiterated a “buy” rating and issued a $72.00 target price on shares of ASLAN Pharmaceuticals in a report on Friday, May 3rd. Piper Sandler reiterated an “overweight” rating and issued a $80.00 price objective (down from $120.00) on shares of ASLAN Pharmaceuticals in a report on Wednesday, March 13th.

ASLAN Pharmaceuticals Stock Down 8.8 %

NASDAQ:ASLN opened at $2.05 on Wednesday. ASLAN Pharmaceuticals has a fifty-two week low of $2.05 and a fifty-two week high of $30.77. The company has a 50 day moving average price of $0.41 and a 200 day moving average price of $0.53.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last posted its earnings results on Thursday, May 9th. The company reported ($10.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.44) by ($4.88). On average, sell-side analysts anticipate that ASLAN Pharmaceuticals will post -2.55 earnings per share for the current year.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases.